SUNNYVALE, Calif., Aug. 23, 2010 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB:ARYC), a leader in life sciences and healthcare technology, announces today that the company has chosen the Premarket Approval (PMA) pathway for its OvaDx® Pre-Symptomatic Ovarian Cancer Screening Test. While the standard for a PMA is higher than for a 510(k), the company believes that a PMA OvaDx® submission can achieve a Class III PMA approval, the most stringent approval level granted by the FDA for in vitro diagnostic devices.
Arrayit Corporation Announces Premarket Approval (PMA) Submission Strategy For OvaDx(R)
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.